Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARO-flare Trial
2025-520482-52-03Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of darolutamide in prostate cancer (PCa) (2 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoints: Number of lesions (primary), Size of lesions (primary) and 8 more. Planned start Dec 2025; status: authorised.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2025-520482-52-03.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520482-52-03.